Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia.

通过血清 des - γ - 羧基凝血酶原筛查和监测 Ia 型糖原累积病患者的肝细胞癌。

• 发表时间: 2024 Jul
• 来源期刊: JIMD Rep
• DOI: 10.1002/jmd2.12414
• PMID: 38974608
• 文章类型: Case Reports
• 作者列表: Schreuder AB,Overduin RJ,Peltenburg NC,de Boer L,Bodewes FAJA,Derks TGJ

关键词: des‐gamma‐carboxy prothrombin; glycogen storage disease type I; hepatocellular adenoma; hepatocellular carcinoma; tumor markers

Abstract

No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha-fetoprotein and carcino-embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des-gamma-carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.

摘要

对于患有糖原贮积病Ia型（GSDIa）的患者，没有肝细胞癌（HCC）的敏感肿瘤标志物。甲胎蛋白和癌胚抗原水平通常保持正常。我们描述了GSDIaHCC患者中HCC肿瘤标志物des-γ-羧基凝血酶原（DCP）的水平升高。在一种情况下，肝移植后DCP水平正常化。我们建议在GSDIa患者的监测中包括DCP作为筛查HCC肿瘤标志物。